Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
一项评估JYP0035 胶囊治疗晚期实体瘤患者的安全性、耐受性及药代动力学特征的开放、多中心、I 期临床研究
[Translation] An open, multicenter, phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of JYP0035 capsules in the treatment of patients with advanced solid tumors
评估JYP0035 胶囊单药治疗晚期实体瘤患者的安全性、耐受性及药代动力学特征的开放、多中心临床研究
[Translation] An open, multicenter clinical study to evaluate the safety, tolerability and pharmacokinetic characteristics of JYP0035 capsule monotherapy in patients with advanced solid tumors
An Open-label Multicenter, Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of JYP0035 Capsule Monotherapy in Patients With Advanced Solid Tumors
The goal of this Phase I clinical trial is to evaluate the safety, tolerability, and pharmacokinetic characteristics of the JYP0035 capsule in patients with advanced solid tumors. The main questions it aims to answer are:
* What is the safety profile of JYP0035 when administered to these patients?
* How does JYP0035 capsule behave in the body pharmacokinetically?
Participants will:
* Receive escalating doses of JYP0035 capsule during the dose-escalation phase (PART-1).
* Continue with the identified dose in the dose-expansion phase (PART-2).
As this is a single-arm study, there is no comparison group.
100 Clinical Results associated with Jiayue (Chengdu) Pharmaceutical Technology Co., Ltd.
0 Patents (Medical) associated with Jiayue (Chengdu) Pharmaceutical Technology Co., Ltd.
100 Deals associated with Jiayue (Chengdu) Pharmaceutical Technology Co., Ltd.
100 Translational Medicine associated with Jiayue (Chengdu) Pharmaceutical Technology Co., Ltd.